Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.
Aged between 18 and 70 years at the time of liver biopsy;
Gender is not limited;
Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4;
Signed written informed consent.
Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases;
Women during pregnancy;
There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation;
Patients considered by the investigator to be unsuitable for this study.
Beijing Municipal Administration of Hospitals
Lead sponsor
Beijing Ditan Hospital
Sponsor institution